﻿<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="document-matrix.xsl"?>
<sub_type_vs_toc version="1.1">
  <section number="1" name="Module 1 Administrative and Prescribing Information" content="" header="yes" elementName="m1-tn"/>
  <section number="1.0" name="Correspondence" content="" header="yes" elementName="m1-0-correspondence"/>
  <section number="1.0.1" name="Cover Letter" content="" elementName="m1-0-1-cover-letter">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="E"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content="E"/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="E"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="E"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="E"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="E"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="E"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="E"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="E"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="E"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="E"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="E"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="E"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="E"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="E"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content="E"/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="E"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="E"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content="E"/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.0.2" name="Note to Evaluator" content="" elementName="m1-0-2-note-to-evaluator">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.0.3" name="Correspondence from ANMPS" content="" elementName="m1-0-3-correspondence-from-authority">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.0.4" name="Response to ANMPS Request" content="" elementName="m1-0-4-response-to-authority">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.0.5" name="Meeting Information" content="" elementName="m1-0-5-meeting-info">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.2" name="Application" content="" header="yes" elementName="m1-2-application"/>
  <section number="1.2.1" name="Application Form" content="" elementName="m1-2-1-application-form">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="E"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="E"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="E"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="E"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="E"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="E"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="E"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="E"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="E"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="E"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="E"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="E"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="E"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content="E"/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="E"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="E"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.2.2" name="Annexes" content="" header="yes" elementName="m1-2-2-annexes"/>
  <section number="1.2.2.1" name="Proof of Payment" content="" elementName="m1-2-2-1-proof-of-payment">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="P"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="P"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="P"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="P"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="P"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="P"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="P"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="P"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="E"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="E"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.2.2.2" name="Letter of Authorisation" content="" elementName="m1-2-2-2-letter-of-authorisation">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="P"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content="P"/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="P"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="P"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="P"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="P"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="P"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="P"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="P"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="P"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="P"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content="P"/>
    <subType code="sub-type-42" displayName="Renewal" content="P"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="P"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.2.2.3" name="Dossier Product Batch Information" content="" elementName="m1-2-2-3-dossier-product-batch-info">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="W"/>
  </section>

  <section number="1.2.2.4" name="Electronic Copy Declaration" content="" elementName="m1-2-2-4-electronic-copy-declaration">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="P"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content="P"/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="P"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="P"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="P"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="P"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="P"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="P"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="P"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="P"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="P"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content="P"/>
    <subType code="sub-type-42" displayName="Renewal" content="P"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content="P"/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.2.2.5" name="Curriculum Vitae of the Person Responsible for Pharmacovigilance" content="" elementName="m1-2-2-5-cv-pharmacovigilance">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content="E"/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.2.2.6" name="Letter of Access from ASMF Holder" content="" elementName="m1-2-2-6-access-letter-asmf">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.2.2.7" name="EMA Certificate for a Vaccine Antigen Master File (VAMF)" content="" elementName="m1-2-2-7-vamf-certificate">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.2.2.8" name="EMA Certificate for a Plasma Master File (PMF)" content="" elementName="m1-2-2-8-pmf-certificate">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.2.2.9" name="Declarations and Attestations" content="" header="yes" elementName="m1-2-2-9-declaration-attestations"/>
  <section number="1.2.2.9.1" name="Declarations and Attestations for Variations" content="" elementName="m1-2-2-9-1-declaration-variations">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="XE"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="XE"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="XE"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="XE"/>
    <subType code="sub-type-24" displayName="Clone" content="XE"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="XE"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="E"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="E"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="E"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="E"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="E"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="E"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="E"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="E"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="E"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="E"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="E"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="E"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="XE"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="XE"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="XE"/>

  </section>
  
  <section number="1.2.2.9.2" name="Declarations and Attestations for Renewals" content="" elementName="m1-2-2-9-2-declaration-renewals">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="XE"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="XE"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="XE"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="XE"/>
    <subType code="sub-type-24" displayName="Clone" content="XE"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="XE"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="XE"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="XE"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="XE"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="XE"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="XE"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="XE"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="XE"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="XE"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="XE"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="XE"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="XE"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="XE"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="XE"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="XE"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="XE"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="XE"/>
  </section>
    
  <section number="1.2.2.9.3" name="Declaration of Sameness for Replicas and Clones" content="" elementName="m1-2-2-9-3-declaration-sameness">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="XE"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="XE"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="XE"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="XE"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="XE"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="XE"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="XE"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="XE"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="XE"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="XE"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="XE"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="XE"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="XE"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="XE"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="XE"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="XE"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="XE"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="XE"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="XE"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="XE"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
      
  <section number="1.2.2.9.A" name="Additional Declarations" content="" elementName="m1-2-2-9-a-additional-declaration">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.2.2.10" name="Application for Priority Review" content="" elementName="m1-2-2-10-priority-review-application">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.2.2.A" name="Additional Annexes" content="" elementName="m1-2-2-a-additional-annexes">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content="NV"/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.2.3" name="Change in Applicant" content="" header="yes" elementName="m1-2-3-change-in-applicant"/>
  <section number="1.2.3.1" name="Letter of Authorisation from Product Owner to New Registrant" content="" elementName="m1-2-3-1-loa-from-prod-owner">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="XE"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="XE"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="XE"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="XE"/>
    <subType code="sub-type-24" displayName="Clone" content="XE"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="XE"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="E"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="XE"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
  
  <section number="1.2.3.2" name="Written Confirmation of Hand-over of Dossier" content="" elementName="m1-2-3-2-confirmation-of-hand-over">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="XE"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="XE"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="XE"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="XE"/>
    <subType code="sub-type-24" displayName="Clone" content="XE"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="XE"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="XE"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content="NV"/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.2.4" name="Patent Information" content="" elementName="m1-2-4-patent-info">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.2.A" name="Additional Administrative Information" content="" elementName="m1-2-a-additional-admin-info">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3" name="Product Information" content="" header="yes" elementName="m1-3-prod-info"/>
  <section number="1.3.1" name="Package Insert" content="" header="yes" elementName="m1-3-1-pi"/>
  <section number="1.3.1.1" name="Professional Information (PI)" content="" header="yes" elementName="m1-3-1-1-pi"/>
  <section number="1.3.1.1.1" name="French PI - Approved" content="" elementName="m1-3-1-1-1-french-pi-approved">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="W"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="W"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="W"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="W"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="W"/>
    <subType code="sub-type-41" displayName="Baseline" content="E"/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="W"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>

  </section>
  
  <section number="1.3.1.1.2" name="French PI - Clean" content="" elementName="m1-3-1-1-2-french-pi-clean">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="P"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="P"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="P"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="P"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="W"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="P"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="E"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="P"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="E"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="E"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="W"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.1.1.3" name="French PI - Annotated" content="" elementName="m1-3-1-1-3-french-pi-annotated">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="P"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="P"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="P"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="P"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="W"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="P"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="E"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="P"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="E"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="E"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="W"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3.1.2" name="Standard References" content="" header="yes" elementName="m1-3-1-2-stdrefs"/>
  <section number="1.3.1.2.1" name="Reference Product - Local" content="" elementName="m1-3-1-2-1-ref-prod-local">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XW"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.1.2.2" name="Reference Product - Foreign" content="" elementName="m1-3-1-2-2-ref-prod-foreign">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="P"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="P"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="P"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
    
  <section number="1.3.1.2.A" name="Other References" content="" elementName="m1-3-1-2-a-other-refs">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3.2" name="Patient Information Leaflet (PIL)" content="" header="yes" elementName="m1-3-2-pil"/>
  <section number="1.3.2.1" name="PIL - Approved" content="" header="yes" elementName="m1-3-2-1-pil-approved"/>
  <section number="1.3.2.1.1" name="French PIL - Approved" content="" elementName="m1-3-2-1-1-french-pil-approved" constrainElement="m1-3-2-1-2-arabic-pil-approved">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="4.6.9(E)"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="4.6.9(E)"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="4.6.9(E)"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="4.6.9(E)"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="4.6.9(E)"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="4.6.9(E)"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="4.6.9(E)"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="4.6.9(E)"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="4.6.9(E)"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="4.6.9(E)"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="4.6.9(E)"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="4.6.9(E)"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="4.6.9(E)"/>
  </section>
  
  <section number="1.3.2.1.2" name="Arabic PIL - Approved" content="" elementName="m1-3-2-1-2-arabic-pil-approved" constrainElement="m1-3-2-1-1-french-pil-approved">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="4.6.9(E)"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="4.6.9(E)"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="4.6.9(E)"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="4.6.9(E)"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="4.6.9(E)"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="4.6.9(E)"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="4.6.9(E)"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="4.6.9(E)"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="4.6.9(E)"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="4.6.9(E)"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="4.6.9(E)"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="4.6.9(E)"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="4.6.9(E)"/>
  </section>
  
  <section number="1.3.2.1.3" name="English PIL - Approved" content="" elementName="m1-3-2-1-3-english-pil-approved">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3.2.2" name="PIL - Clean" content="" header="yes" elementName="m1-3-2-2-pil-clean"/>
  <section number="1.3.2.2.1" name="French PIL - Clean" content="" elementName="m1-3-2-2-1-french-pil-clean" constrainElement="m1-3-2-2-2-arabic-pil-clean">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="P"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="4.6.10(E)"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="4.6.10(E)"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="4.6.10(E)"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="4.6.10(E)"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.2.2.2" name="Arabic PIL - Clean" content="" elementName="m1-3-2-2-2-arabic-pil-clean" constrainElement="m1-3-2-2-1-french-pil-clean">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="P"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="4.6.10(E)"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="4.6.10(E)"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="4.6.10(E)"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="4.6.10(E)"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.2.2.3" name="English PIL - Clean" content="" elementName="m1-3-2-2-3-english-pil-clean">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3.2.3" name="PIL - Annotated" content="" header="yes" elementName="m1-3-2-3-pil-annotated"/>
  <section number="1.3.2.3.1" name="French PIL - Annotated" content="" elementName="m1-3-2-3-1-french-pil-annotated" constrainElement="m1-3-2-3-2-arabic-pil-annotated">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="P"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="4.6.11(E)"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="4.6.11(E)"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="4.6.11(E)"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="4.6.11(E)"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.2.3.2" name="Arabic PIL - Annotated" content="" elementName="m1-3-2-3-2-arabic-pil-annotated" constrainElement="m1-3-2-3-1-french-pil-annotated">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="P"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="4.6.11(E)"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="4.6.11(E)"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="4.6.11(E)"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="4.6.11(E)"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
    
  <section number="1.3.2.3.3" name="English PIL - Annotated" content="" elementName="m1-3-2-3-3-english-pil-annotated">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>

  </section>
  
  <section number="1.3.3" name="Labels" content="" header="yes" elementName="m1-3-3-labels"/>
  <section number="1.3.3.1" name="Labels - Approved" content="" header="yes" elementName="m1-3-3-1-labels-approved"/>
  <section number="1.3.3.1.1" name="French Labels - Approved" elementName="m1-3-3-1-1-french-label-approved" constrainElement="m1-3-3-1-2-arabic-label-approved">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="4.6.12(E)"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="4.6.12(E)"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="4.6.12(E)"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="4.6.12(E)"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="4.6.12(E)"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="4.6.12(E)"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="4.6.12(E)"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="4.6.12(E)"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="4.6.12(E)"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="4.6.12(E)"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="4.6.12(E)"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="4.6.12(E)"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="4.6.12(E)"/>
  </section>
  
  <section number="1.3.3.1.2" name="Arabic Labels - Approved" content="" elementName="m1-3-3-1-2-arabic-label-approved" constrainElement="m1-3-3-1-1-french-label-approved">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="4.6.12(E)"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="4.6.12(E)"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="4.6.12(E)"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="4.6.12(E)"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="4.6.12(E)"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="4.6.12(E)"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="4.6.12(E)"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="4.6.12(E)"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="4.6.12(E)"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="4.6.12(E)"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="4.6.12(E)"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="4.6.12(E)"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="4.6.12(E)"/>
  </section>
  
  <section number="1.3.3.1.3" name="English Labels - Approved" content="" elementName="m1-3-3-1-3-english-label-approved">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3.3.2" name="Labels - Clean" content="" header="yes" elementName="m1-3-3-2-labels-clean"/>
  <section number="1.3.3.2.1" name="French Labels - Clean" elementName="m1-3-3-2-1-french-label-clean">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.3.2.2" name="Arabic Labels - Clean" content="" elementName="m1-3-3-2-2-arabic-label-clean">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.3.2.3" name="English Labels - Clean" content="" elementName="m1-3-3-2-3-english-label-clean">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3.3.3" name="Labels - Annotated" content="" header="yes" elementName="m1-3-3-3-labels-annotated"/>
  <section number="1.3.3.3.1" name="French Labels - Annotated" content="" elementName="m1-3-3-3-1-french-label-annotated">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.3.3.2" name="Arabic Labels - Annotated" content="" elementName="m1-3-3-3-2-arabic-label-annotated">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.3.3.3" name="English Labels - Annotated" content="" elementName="m1-3-3-3-3-english-label-annotated">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3.4" name="Braille" content="" elementName="m1-3-4-braille">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.3.5" name="Foreign Product Information" content="" elementName="m1-3-5-foreign-product-info">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="W"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="W"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="P"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
  <section number="1.3.6" name="Artwork and Samples" content="" header="yes" elementName="m1-3-6-artwork-samples"/>
  <section number="1.3.6.1" name="Statement Confirming Submission of Samples" content="" elementName="m1-3-6-1-statement-of-samples">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
  
  <section number="1.3.6.2" name="Artwork" content="" elementName="m1-3-6-2-artwork">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="P"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="P"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="P"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="P"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content="E"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>
  
  <section number="1.3.6.3" name="Pictures of Samples" content="" elementName="m1-3-6-3-pictures-of-samples">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="W"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
  
  <section number="1.3.6.4" name="Batch Manufacturing Record of the Sample" content="" elementName="m1-3-6-4-batch-of-samples">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.3.6.5" name="CoA of the Sample" content="" elementName="m1-3-6-5-coa-samples">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="W"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.4" name="Information about the Experts" content="" header="yes" elementName="m1-4-expert-information"/>
  <section number="1.4.1" name="Quality" content="" elementName="m1-4-1-quality">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
  
  <section number="1.4.2" name="Nonclinical" content="" elementName="m1-4-2-non-clinical">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
    
  <section number="1.4.3" name="Clinical" content="" elementName="m1-4-3-clinical">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.5" name="Specific Requirements for different Types of Applications" content="" header="yes" elementName="m1-5-specific-requirements"/>
  <section number="1.5.1" name="Literature Based Submissions" content="" elementName="m1-5-1-literature-based">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XW"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XW"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="XW"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
  
  <section number="1.5.2" name="Proprietary Name Applications and Changes" content="" elementName="m1-5-2-proprietary-name">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.5.3" name="Genetically Modified Organisms" content="" elementName="m1-5-3-gmo">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.5.4" name="Generic Applications (BTIF)" content="" header="yes" elementName="m1-5-4-generic"/>
  <section number="1.5.4.1" name="BTIF" content="" elementName="m1-5-4-1-btif">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="W"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="W"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="W"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="XE"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="W"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.5.4.2" name="Biowaiver" content="" elementName="m1-5-4-2-biowaiver">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="XE"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="W"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="W"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="W"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="W"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.5.5" name="Abridged Applications" content="" elementName="m1-5-5-abridged">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XW"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.5.A" name="Additional Types of Applications Specific Requirements" content="" elementName="m1-5-a-additional-types">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="1.6" name="Environmental Risk Assessment" content="" header="yes" elementName="m1-6-environ-risk-assessment"/>
  <section number="1.6.1" name="Non-GMO (Genetically Modified Organisms)" content="" elementName="m1-6-1-nongmo">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.6.2" name="GMO (Genetically Modified Organisms)" content="" elementName="m1-6-2-gmo">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.7" name="Good Manufacturing Practice" content="" header="yes" elementName="m1-7-gmp"/>
  <section number="1.7.1" name="Date of Last Inspection of each Site" content="" elementName="m1-7-1-last-inspection">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.7.2" name="Inspection Reports or Equivalent Document" content="" elementName="m1-7-2-inspection-report-or-equivalent">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.7.3" name="Latest GMP Certificate or a Copy of the Appropriate Licence" content="" elementName="m1-7-3-gmp-certificate">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="P"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="P"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="P"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="P"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.7.4" name="Confirmation of Contract" content="" elementName="m1-7-4-contract-confirmation">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>
  
  <section number="1.7.5" name="Case of Subcontracting" content="" elementName="m1-7-5-case-of-subcontracting">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.7.6" name="Establishment license or Company Registration of Foreign Applicant" content="" elementName="m1-7-6-licencing-or-registration">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="P"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="P"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="P"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="P"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>
  
  <section number="1.7.7" name="Other Documents Relating to the Applicant" content="" elementName="m1-7-7-docs-applicant">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.7.8" name="Production Flow Diagrams" content="" header="yes" elementName="m1-7-8-production-flow-diagram"/>
  <section number="1.7.8.1" name="Inspection Flow Diagram" content="" elementName="m1-7-8-1-inspection-flow-diagram">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>
  
  <section number="1.7.8.2" name="Distribution Flow Diagram" content="" elementName="m1-7-8-2-distribution-flow-diagram">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.7.A" name="Additional GXP Documents" content="" elementName="m1-7-a-additional-gxp-documents">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>
  
  <section number="1.8" name="Information Relating to Pharmacovigilance" content="" header="yes" elementName="m1-8-info-relating-pv"/>
  <section number="1.8.1" name="Pharmacovigilance Systems" content="" elementName="m1-8-1-pv-systems">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="E"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="E"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="NV"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.8.2" name="Risk Management Plan" content="" elementName="m1-8-2-risk-management-plan">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="P"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.9" name="Individual Patient Data - Statement of Availability" content="" header="yes" elementName="m1-9-indiv-patient-data">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content="NV"/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.10" name="Foreign Regulatory Status" content="" header="yes" elementName="m1-10-foreign-reg-status"/>
  <section number="1.10.1" name="Tabulated List of Foreign Regulatory Status" content="" elementName="m1-10-1-countries-same-appl">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="W"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="W"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="W"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="W"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="W"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="W"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="W"/>
  </section>

  <section number="1.10.2" name="Registration Certificate or Marketing Authorisation" content="" elementName="m1-10-2-foreign-reg-certif-or-ma">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="W"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="W"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="W"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="W"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="W"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="W"/>
  </section>

  <section number="1.10.3" name="Foreign Evaluation Reports" content="" elementName="m1-10-3-foreign-eval-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="P"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.10.4" name="Data Set Similarities" content="" header="yes" elementName="m1-10-4-data-set-similarities"/>
  <section number="1.10.4.1" name="Data Set Similarities" content="" elementName="m1-10-4-1-data-set-similarities">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.10.4.2" name="Declaration of Sameness" content="" elementName="m1-10-4-2-declaration-sameness">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="P"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="P"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="P"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="P"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.10.5" name="CPP (WHO certification scheme)" content="" elementName="m1-10-5-cpp">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="P"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="P"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="W"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="W"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="P"/>
  </section>

  <section number="1.11" name="Paediatric Development Programme" content="" header="yes" elementName="m1-11-paediatric-dev-program">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="1.12" name="Information on the Price" content="" header="yes" elementName="m1-12-pricing"/>
  <section number="1.12.1" name="Price Proposal" content="" elementName="m1-12-1-price-proposal">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.12.2" name="Daily Cost Treatment and/or Cost per Cure" content="" elementName="m1-12-2-daily-or-per-cure-cost">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="E"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="E"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="E"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="E"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="E"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="E"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="E"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="E"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="E"/>
  </section>

  <section number="1.12.3" name="Price Certification" content="" elementName="m1-12-3-price-certification">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="W"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="W"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="W"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="W"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="W"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="W"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="W"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="W"/>
  </section>

  <section number="1.12.4" name="Price List in the other Countries" content="" elementName="m1-12-4-price-list">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="W"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="W"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="W"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="W"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="W"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="W"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="W"/>
  </section>

  <section number="1.12.5" name="Refund Status and Corresponding Rate" content="" elementName="m1-12-5-refund">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="W"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="W"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="W"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="W"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="W"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="W"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="W"/>
  </section>

  <section number="1.A" name="Additional Data" content="" elementName="m1-a-additional-data">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="2" name="Summaries and Overviews" content="" header="yes" elementName="m2-common-technical-document-summaries"/>
  <section number="2.2" name="Introduction" content="" elementName="m2-2-introduction">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.3" name="Quality Overall Summary" content="" header="yes" elementName="m2-3-quality-overall-summary"/>
  <section number="2.3" name="WHO QOS" content="" elementName="m2-3-introduction">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="W"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="W"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="W"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="W"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="W"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="W"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="W"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="W"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="W"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content="NV"/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content="NV"/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content="NV"/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content="NV"/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content="NV"/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content="NV"/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content="NV"/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content="NV"/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content="NV"/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content="NV"/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content="NV"/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content="NV"/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content="NV"/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content="NV"/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content="NV"/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content="NV"/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content="NV"/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content="NV"/>
  </section>

  <section number="2.3" name="WHO QIS" content="" elementName="m2-3-introduction">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.3.R" name="Regional Information" content="" elementName="m2-3-r-regional-information">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.4" name="Nonclinical Overview" content="" elementName="m2-4-nonclinical-overview">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.5" name="Clinical Overview" content="" elementName="m2-5-clinical-overview">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.6" name="Nonclinical Summaries" content="" header="yes" elementName="m2-6-nonclinical-written-and-tabulated-summaries"/>
  <section number="2.6.1" name="Introduction" content="" elementName="m2-6-1-introduction">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.6.2" name="Pharmacology Written Summary" content="" elementName="m2-6-2-pharmacology-written-summary">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.6.3" name="Pharmacology Tabulated Summary" content="" elementName="m2-6-3-pharmacology-tabulated-summary">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.6.4" name="Pharmacokinetics Written Summary" content="" elementName="m2-6-4-pharmacokinetics-written-summary">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.6.5" name="Pharmacokinetics Tabulated Summary" content="" elementName="m2-6-5-pharmacokinetics-tabulated-summary">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.6.6" name="Toxicology Written Summary" content="" elementName="m2-6-6-toxicology-written-summary">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.6.7" name="Toxicology Tabulated Summary" content="" elementName="m2-6-7-toxicology-tabulated-summary">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.7" name="Clinical Summaries" content="" header="yes" elementName="m2-7-clinical-summary"/>
  <section number="2.7.1" name="Summary of Biopharmaceutic Studies and Associated Analytical Methods" content="" elementName="m2-7-1-summary-of-biopharmaceutic-studies-and-associated-analytical-methods">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.7.2" name="Summary of Clinical Pharmacology Studies" content="" elementName="m2-7-2-summary-of-clinical-pharmacology-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.7.3" name="Summary of Clinical Efficacy" content="" elementName="m2-7-3-summary-of-clinical-efficacy">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.7.4" name="Summary of Clinical Safety" content="" elementName="m2-7-4-summary-of-clinical-safety">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.7.5" name="Literature References" content="" elementName="m2-7-5-literature-references">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="2.7.6" name="Synopsis of Individual Studies" content="" elementName="m2-7-6-synopses-of-individual-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3" name="Quality" content="" header="yes" elementName="m3-quality"/>
  <section number="3.2" name="Body of Data" content="" header="yes" elementName="m3-2-body-of-data"/>
  <section number="3.2.S" name="Drug Substance" content="" header="yes" elementName="m3-2-s-drug-substance"/>
  <section number="3.2.S.1" name="General Information" content="" header="yes" elementName="m3-2-s-1-general-information"/>
  <section number="3.2.S.1.1" name="Nomenclature" content="" elementName="m3-2-s-1-1-nomenclature">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.1.2" name="Structure" content="" elementName="m3-2-s-1-2-structure">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.1.3" name="General Properties" content="" elementName="m3-2-s-1-3-general-properties">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.2" name="Manufacturer" content="" header="yes" elementName="m3-2-s-2-manufacture"/>
  <section number="3.2.S.2.1" name="Manufacturer(s)" content="" elementName="m3-2-s-2-1-manufacturer">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.2.2" name="Description of Manufacturing Process and Process Controls" content="" elementName="m3-2-s-2-2-description-of-manufacturing-process-and-process-controls">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.2.3" name="Control of Materials" content="" elementName="m3-2-s-2-3-control-of-materials">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.2.4" name="Control of Critical Steps and Intermediates" content="" elementName="m3-2-s-2-4-controls-of-critical-steps-and-intermediates">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.2.5" name="Process Validation and/or Evaluation" content="" elementName="m3-2-s-2-5-process-validation-and-or-evaluation">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.2.6" name="Container Closure System" content="" elementName="m3-2-s-2-6-manufacturing-process-development">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.S.3" name="Characterisation" content="" header="yes" elementName="m3-2-s-3-characterisation"/>
  <section number="3.2.S.3.1" name="Elucidation of Structure and Other Characteristics" content="" elementName="m3-2-s-3-1-elucidation-of-structure-and-other-characteristics">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.3.2" name="Impurities" content="" elementName="m3-2-s-3-2-impurities">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.4" name="Control of Drug Substance" content="" header="yes" elementName="m3-2-s-4-control-of-drug-substance"/>
  <section number="3.2.S.4.0" name="Control Strategy" content="" elementName="m3-2-s-4-control-of-drug-substance">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.S.4.1" name="Specification" content="" elementName="m3-2-s-4-1-specification">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.4.2" name="Analytical Procedures" content="" elementName="m3-2-s-4-2-analytical-procedures">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.4.3" name="Validation of Analytical Procedures" content="" elementName="m3-2-s-4-3-validation-of-analytical-procedures">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.4.4" name="Batch Analyses" content="" elementName="m3-2-s-4-4-batch-analyses">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.4.5" name="Justification of Specification" content="" elementName="m3-2-s-4-5-justification-of-specification">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.5" name="Reference Standards or Materials" content="" elementName="m3-2-s-5-reference-standards-or-materials">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.6" name="Container Closure System" content="" elementName="m3-2-s-6-container-closure-system">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.7" name="Stability" content="" header="yes" elementName="m3-2-s-7-stability"/>
  <section number="3.2.S.7.1" name="Stability Summary and Conclusions" content="" elementName="m3-2-s-7-1-stability-summary-and-conclusions">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.7.2" name="Post-approval Stability Protocol and Stability Commitment" content="" elementName="m3-2-s-7-2-post-approval-stability-protocol-and-stability-commitment">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.S.7.3" name="Stability Data" content="" elementName="m3-2-s-7-3-stability-data">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.P" name="Drug Product" content="" header="yes" elementName="m3-2-p-drug-product"/>
  <section number="3.2.P.1" name="Description and Composition of the Drug Product" content="" elementName="m3-2-p-1-description-and-composition-of-the-drug-product">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.2" name="Pharmaceutical Development" content="" elementName="m3-2-p-2-pharmaceutical-development">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.3" name="Manufacture" content="" header="yes" elementName="m3-2-p-3-manufacture"/>
  <section number="3.2.P.3.1" name="Manufacture(s)" content="" elementName="m3-2-p-3-1-manufacturers">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.P.3.2" name="Batch Formula" content="" elementName="m3-2-p-3-2-batch-formula">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.P.3.3" name="Description of Manufacturing Process Controls" content="" elementName="m3-2-p-3-3-description-of-manufacturing-process-and-process-controls">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.P.3.4" name="Controls of Critical Steps and Intermediates" content="" elementName="m3-2-p-3-4-controls-of-critical-steps-and-intermediates">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.P.3.5" name="Process Validation and/or Evaluation" content="" elementName="m3-2-p-3-5-process-validation-and-or-evaluation">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.P.4" name="Control of Excipients" content="" header="yes" elementName="m3-2-p-4-control-of-excipients"/>
  <section number="3.2.P.4.1" name="Specifications" content="" elementName="m3-2-p-4-1-specifications">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.4.2" name="Analytical Procedures" content="" elementName="m3-2-p-4-2-analytical-procedures">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.4.3" name="Validation of Analytical Procedures" content="" elementName="m3-2-p-4-3-validation-of-analytical-procedures">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.4.4" name="Justification of Specifications" content="" elementName="m3-2-p-4-4-justification-of-specifications">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.4.5" name="Excipients of Human or Animal Origin" content="" elementName="m3-2-p-4-5-excipients-of-human-or-animal-origin">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.4.6" name="Novel Excipients" content="" elementName="m3-2-p-4-6-novel-excipients">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.5" name="Control of Drug Product" content="" header="yes" elementName="m3-2-p-5-control-of-drug-product"/>
  <section number="3.2.P.5.0" name="Control Strategy" content="" elementName="m3-2-p-5-control-of-drug-product">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.5.1" name="Specification" content="" elementName="m3-2-p-5-1-specifications">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.5.2" name="Analytical Procedures" content="" elementName="m3-2-p-5-2-analytical-procedures">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.5.3" name="Validation of Analytical Procedures" content="" elementName="m3-2-p-5-3-validation-of-analytical-procedures">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.5.4" name="Batch Analyses" content="" elementName="m3-2-p-5-4-batch-analyses">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.5.5" name="Characterisation of Impurities" content="" elementName="m3-2-p-5-5-characterisation-of-impurities">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.5.6" name="Justification of Specification" content="" elementName="m3-2-p-5-6-justification-of-specifications">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.6" name="Reference Standards or Materials" content="" elementName="m3-2-p-6-reference-standards-or-materials">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.7" name="Container Closure System" content="" elementName="m3-2-p-7-container-closure-system">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.8" name="Stability" content="" header="yes" elementName="m3-2-p-8-stability"/>
  <section number="3.2.P.8.1" name="Stability Summary and Conclusions" content="" elementName="m3-2-p-8-1-stability-summary-and-conclusion">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.P.8.2" name="Post-approval Stability Protocol and Stability" content="" elementName="m3-2-p-8-2-post-approval-stability-protocol-and-stability-commitment">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="3.2.P.8.3" name="Stability Data" content="" elementName="m3-2-p-8-3-stability-data">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="3.2.A" name="Appendices" content="" header="yes" elementName="m3-2-a-appendices"/>
  <section number="3.2.A.1" name="Facilities and Equipment" content="" elementName="m3-2-a-1-facilities-and-equipment">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.A.2" name="Adventitious Agents Safety Evaluation" content="" elementName="m3-2-a-2-adventitious-agents-safety-evaluation">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.A.3" name="Excipient" content="" elementName="m3-2-a-3-excipients">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R" name="Regional Information" content="" header="yes" elementName="m3-2-r-regional-information"/>
  <section number="3.2.R.1" name="Production Documentation" content="" header="yes" elementName="node-extension-Production-Documentation"/>
  <section number="3.2.R.1.1" name="Executed Batch Records" content="" elementName="32r11-executed-br">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.1.2" name="Executed Product Documents (CoA)" content="" elementName="32r12-executed-prod-doc">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.1.3" name="Master Production Documents (Blank)" content="" elementName="32r13-master-prod-doc">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="E"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="E"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content="NV"/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.2" name="Tech Transfer" content="" header="yes" elementName="node-extension-Tech-Transfer"/>
  <section number="3.2.R.2.1" name="Protocol" content="" elementName="32r21-protocol">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.2.2" name="Reports" content="" elementName="32r22-report">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.2.A" name="Additional Tech Transfer Documentation" content="" elementName="32r2a-add-tech-transfer-docs">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="NV"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="NV"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="NV"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.3" name="CEP" content="" header="yes" elementName="32r3-cep">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content="P"/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content="P"/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content="P"/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.4" name="Comparability Studies" content="" header="yes" elementName="node-extension-Comparability-Studies"/>
  <section number="3.2.R.4.1" name="Medical Device Similarity" content="" elementName="32r41-med-dev-similar">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.4.2" name="Biosimilars" content="" elementName="32r42-biosimilars">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="XE"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="XE"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="XE"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="XE"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="XE"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="E"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.R.4.A" name="Additional Comparability Studies" content="" elementName="32r4a-add-comparability-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.5" name="Medical Devices" header="yes" content="" elementName="32r5-medical-devices">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.2.R.6" name="BSE TSE Documents" header="yes" content="" elementName="32r6-bse-tse">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="P"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="P"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="P"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="P"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="P"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="P"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="3.2.R.A" name="Additional Regional Information" header="yes" content="" elementName="32ra-add-region-info">
    <subType code="sub-type-1" displayName="New Chemical Entity" content="NV"/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content="NV"/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content="NV"/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content="NV"/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content="NV"/>
    <subType code="sub-type-11" displayName="New Biosimilar" content="NV"/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="3.3" name="Literature References" content="" header="yes" elementName="m3-3-literature-references"/>
  <section number="" name="[AUTHOR DATE]" content="" elementName="m3-3-literature-references">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4" name="Nonclinical Study Reports" content="" header="yes" elementName="m4-nonclinical-study-reports"/>
  <section number="4.2" name="Study Reports" content="" header="yes" elementName="m4-2-study-reports"/>
  <section number="4.2.1" name="Pharmacodynamics" content="" header="yes" elementName="m4-2-1-pharmacology"/>
  <section number="4.2.1.1" name="Primary Pharmacodynamics" content="" elementName="m4-2-1-1-primary-pharmacodynamics">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.1.2" name="Secondary Pharmacodynamics" content="" elementName="m4-2-1-2-secondary-pharmacodynamics">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.1.3" name="Safety Pharmacology" content="" elementName="m4-2-1-3-safety-pharmacology">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.1.4" name="Pharmacodynamic Drug Interactions" content="" elementName="m4-2-1-4-pharmacodynamic-drug-interactions">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.2" name="Pharmacokinetics" content="" header="yes" elementName="m4-2-2-pharmacokinetics"/>
  <section number="4.2.2.1" name="Analytical Methods and Validation Reports" content="" elementName="m4-2-2-1-analytical-methods-and-validation-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.2.2" name="Absorption" content="" elementName="m4-2-2-2-absorption">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.2.3" name="Distribution" content="" elementName="m4-2-2-3-distribution">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.2.4" name="Metabolism" content="" elementName="m4-2-2-4-metabolism">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.2.5" name="Excretion" content="" elementName="m4-2-2-5-excretion">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.2.6" name="Pharmacokinetic Drug Interactions" content="" elementName="m4-2-2-6-pharmacokinetic-drug-interactions">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.2.7" name="Other Pharmacokinetic Studies" content="" elementName="m4-2-2-7-other-pharmacokinetic-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.3" name="Toxicology" content="" header="yes" elementName="m4-2-3-toxicology"/>
  <section number="4.2.3.1" name="Single Dose Toxicity" content="" elementName="m4-2-3-1-single-dose-toxicity">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.2" name="Repeat Dose Toxicity" content="" elementName="m4-2-3-2-repeat-dose-toxicity">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.3" name="Genotoxicity" content="" header="yes" elementName="m4-2-3-3-genotoxicity"/>
  <section number="4.2.3.3.1" name="In Vitro" content="" elementName="m4-2-3-3-1-in-vitro">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.3.3.2" name="In Vivo" content="" elementName="m4-2-3-3-2-in-vivo">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.3.4" name="Carcinogenicity" content="" header="yes" elementName="m4-2-3-4-carcinogenicity"/>
  <section number="4.2.3.4.1" name="Long-term Studies" content="" elementName="m4-2-3-4-1-long-term-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.4.2" name="Short- or Medium-term Studies" content="" elementName="m4-2-3-4-2-short-or-medium-term-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.4.3" name="Other Studies" content="" elementName="m4-2-3-4-3-other-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.5" name="Reproductive and Developmental Toxicity" content="" header="yes" elementName="m4-2-3-5-reproductive-and-developmental-toxicity"/>
  <section number="4.2.3.5.1" name="Fertility and Early Embryonic Development" content="" elementName="m4-2-3-5-1-fertility-and-early-embryonic-development">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.5.2" name="Embryo-fetal Development" content="" elementName="m4-2-3-5-2-embryo-fetal-development">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="4.2.3.5.3" name="Prenatal and Postnatal Development, including Maternal Function" content="" elementName="m4-2-3-5-3-prenatal-and-postnatal-development-including-maternal-function">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
      
  <section number="4.2.3.5.4" name="Studies in which the Offspring are Dosed and/or Further Evaluated" content="" elementName="m4-2-3-5-4-studies-in-which-the-offspring-juvenile-animals-are-dosed-and-or-further-evaluated">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
      
  <section number="4.2.3.6" name="Local Tolerance" content="" elementName="m4-2-3-6-local-tolerance">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.7" name="Other Toxicity Studies" content="" header="yes" elementName="m4-2-3-7-other-toxicity-studies"/>
  <section number="4.2.3.7.1" name="Antigenicity" content="" elementName="m4-2-3-7-1-antigenicity">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.7.2" name="Immunotoxicity" content="" elementName="m4-2-3-7-2-immunotoxicity">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.7.3" name="Mechanistic Studies" content="" elementName="m4-2-3-7-3-mechanistic-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.7.4" name="Dependence" content="" elementName="m4-2-3-7-4-dependence">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.7.5" name="Metabolites" content="" elementName="m4-2-3-7-5-metabolites">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.7.6" name="Impurities" content="" elementName="m4-2-3-7-6-impurities">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.2.3.7.7" name="Other" content="" elementName="m4-2-3-7-7-other">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="4.3" name="Literature References" content="" header="yes" elementName="m4-3-literature-references"/>
  <section number="" name="[AUTHOR DATE]" content="" elementName="m4-3-literature-references">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5" name="Clinical Study Reports" content="" header="yes" elementName="m5-clinical-study-reports"/>
  <section number="5.2" name="Tabular Listing of All Clinical Studies" content="" elementName="m5-2-tabular-listing-of-all-clinical-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3" name="Clinical Study Reports" content="" header="yes" elementName="m5-3-clinical-study-reports"/>
  <section number="5.3.1" name="Reports of Biopharmaceutic Studies" content="" header="yes" elementName="m5-3-1-reports-of-biopharmaceutic-studies"/>
  <section number="5.3.1.1" name="Bioavailability (BA) Study Reports" content="" elementName="m5-3-1-1-bioavailability-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.1.2" name="Comparative BA and Bioequivalence (BE) Study Reports" content="" elementName="m5-3-1-2-comparative-ba-and-bioequivalence-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="5.3.1.3" name="In Vitro - In Vivo Correlation Study Reports" content="" elementName="m5-3-1-3-in-vitro-in-vivo-correlation-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
      
  <section number="5.3.1.4" name="Reports of Bioanalytical and Analytical Methods for Human Studies" content="" elementName="m5-3-1-4-reports-of-bioanalytical-and-analytical-methods-for-human-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.2" name="Reports of Studies Pertinent to Pharmacokinetics using Human Biomaterials" content="" header="yes" elementName="m5-3-2-reports-of-studies-pertinent-to-pharmacokinetics-using-human-biomaterials"/>
  <section number="5.3.2.1" name="Plasma Protein Binding Study Reports" content="" elementName="m5-3-2-1-plasma-protein-binding-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.2.2" name="Reports of Hepatic metabolism and Drug Interaction Studies" content="" elementName="m5-3-2-2-reports-of-hepatic-metabolism-and-drug-interaction-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.2.3" name="Reports of Studies Using Other Human Biomaterials" content="" elementName="m5-3-2-3-reports-of-studies-using-other-human-biomaterials">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.3" name="Reports of Human Pharmacokinetic (PK) Studies" content="" header="yes" elementName="m5-3-3-reports-of-human-pharmacokinetics-pk-studies"/>
  <section number="5.3.3.1" name="Healthy Subject PK and Initial Tolerability Study Reports" content="" elementName="m5-3-3-1-healthy-subject-pk-and-initial-tolerability-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="5.3.3.2" name="Patient PK and Initial Tolerability Study Reports" content="" elementName="m5-3-3-2-patient-pk-and-initial-tolerability-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.3.3" name="Intrinsic Factor PK Study Reports" content="" elementName="m5-3-3-3-intrinsic-factor-pk-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="5.3.3.4" name="Extrinsic Factor PK Study Reports" content="" elementName="m5-3-3-4-extrinsic-factor-pk-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
      
  <section number="5.3.3.5" name="Population PK Study Reports" content="" elementName="m5-3-3-5-population-pk-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
      
  <section number="5.3.4" name="Reports of Human Pharmacodynamic (PD) Studies" content="" header="yes" elementName="m5-3-4-reports-of-human-pharmacodynamics-pd-studies"/>
  <section number="5.3.4.1" name="Healthy Subject PD and PK/PD Study Reports" content="" elementName="m5-3-4-1-healthy-subject-pd-and-pk-pd-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.4.2" name="Patient PD and PK/PD Study Reports" content="" elementName="m5-3-4-2-patient-pd-and-pk-pd-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.5" name="Reports of Efficacy and Safety Studies" content="" header="yes" elementName="m5-3-5-reports-of-efficacy-and-safety-studies"/>
  <section number="5.3.5.1" name="Study Reports of Controlled Clinical Studies Pertinent to the Claimed Indication" content="" elementName="m5-3-5-1-study-reports-of-controlled-clinical-studies-pertinent-to-the-claimed-indication">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.5.2" name="Study Reports of Uncontrolled Clinical Studies" content="" elementName="m5-3-5-2-study-reports-of-uncontrolled-clinical-studies">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.5.3" name="Reports of Analyses of Data from More than One Study" content="" elementName="m5-3-5-3-reports-of-analyses-of-data-from-more-than-one-study">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
    
  <section number="5.3.5.4" name="Other Study Reports" content="" elementName="m5-3-5-4-other-study-reports">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
  
  <section number="5.3.6" name="Reports of Postmarketing Experience" content="" header="yes" elementName="m5-3-6-reports-of-postmarketing-experience"/>
  <section number="5.3.6.1" name="PBRER [DESCRIPTION] [DATE/DATA LOCK PERIOD]" content="" elementName="5.3.6.1">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="5.3.6.2" name="PBRER [DESCRIPTION] [DATE/DATA LOCK PERIOD]" content="" elementName="5.3.6.2">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="5.3.6.3" name="RMP Report [DESCRIPTION] [DATE/DATA LOCK PERIOD]" content="" elementName="5.3.6.3">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content="P"/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="5.3.7" name="Case Report Forms and Individual Patient Listings" content="" header="yes" elementName="m5-3-7-case-report-forms-and-individual-patient-listings"/>
  <section number="5.3.7.1" name="CRFs of deaths, other serious adverse events and withdrawals for AE" content="" elementName="m5-3-7-case-report-forms-and-individual-patient-listings">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="5.3.7.2" name="Other CRFs submitted" content="" elementName="m5-3-7-case-report-forms-and-individual-patient-listings">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>

  <section number="5.4" name="Literature References" content="" header="yes" elementName="m5-4-literature-references"/>
  <section number="" name="[AUTHOR DATE]" content="" elementName="m5-4-literature-references">
    <subType code="sub-type-1" displayName="New Chemical Entity" content=""/>
    <subType code="sub-type-2" displayName="New Combination" content="" />
    <subType code="sub-type-3" displayName="New Generic (Multi-source)" content=""/>
    <subType code="sub-type-4" displayName="New OTC" content=""/>
    <subType code="sub-type-5" displayName="New Complementary" content=""/>
    <subType code="sub-type-6" displayName="New Vaccine" content=""/>
    <subType code="sub-type-7" displayName="New Radiopharmaceutical" content=""/>
    <subType code="sub-type-8" displayName="New Gene and Cell Therapy" content=""/>
    <subType code="sub-type-9" displayName="New Blood Product" content=""/>
    <subType code="sub-type-10" displayName="New Biotherapeutic" content=""/>
    <subType code="sub-type-11" displayName="New Biosimilar" content=""/>
    <subType code="sub-type-12" displayName="New Traditional" content=""/>
    <subType code="sub-type-13" displayName="New Clinical Trial Application" content=""/>
    <subType code="sub-type-14" displayName="New Excipient" content=""/>
    <subType code="sub-type-15" displayName="New ASMF / DMF" content=""/>
    <subType code="sub-type-16" displayName="New Plasma Master File (PMF)" content=""/>
    <subType code="sub-type-17" displayName="New Vaccine Antigen Master File (VAMF)" content=""/>
    <subType code="sub-type-18" displayName="New Tissue Master File (TMF)" content=""/>
    <subType code="sub-type-19" displayName="New Biological Master File (BMF)" content=""/>
    <subType code="sub-type-20" displayName="Line Extension - New Dosage Form" content=""/>
    <subType code="sub-type-21" displayName="Line Extension - New Strength" content=""/>
    <subType code="sub-type-22" displayName="Line Extension - New Route of Administration" content=""/>
    <subType code="sub-type-23" displayName="Line Extension - New Application" content=""/>
    <subType code="sub-type-24" displayName="Clone" content=""/>
    <subType code="sub-type-25" displayName="Replica - Additional Product (Same)" content=""/>
    <subType code="sub-type-26" displayName="Post Approval Commitment" content=""/>
    <subType code="sub-type-27" displayName="VT Immediate Notification - Administrative" content=""/>
    <subType code="sub-type-28" displayName="VT Annual Notification - Administrative" content=""/>
    <subType code="sub-type-29" displayName="VT Annual Notification - Quality" content=""/>
    <subType code="sub-type-30" displayName="VT Immediate Notification - Quality" content=""/>
    <subType code="sub-type-31" displayName="VT Immediate Notification - Clinical" content=""/>
    <subType code="sub-type-32" displayName="VT Minor - Quality" content=""/>
    <subType code="sub-type-33" displayName="VT Minor - Clinical" content=""/>
    <subType code="sub-type-34" displayName="VT Minor - Other" content=""/>
    <subType code="sub-type-35" displayName="VT Moderate - Quality" content=""/>
    <subType code="sub-type-36" displayName="VT Major - Safety (Clinical)" content=""/>
    <subType code="sub-type-37" displayName="VT Major - Safety and Efficacy (Clinical)" content=""/>
    <subType code="sub-type-38" displayName="VT Major - Quality" content=""/>
    <subType code="sub-type-39" displayName="VT Major - Change in Applicant - Relinquishing" content=""/>
    <subType code="sub-type-40" displayName="VT Major - Change in Applicant - Acquiring" content=""/>
    <subType code="sub-type-41" displayName="Baseline" content=""/>
    <subType code="sub-type-42" displayName="Renewal" content=""/>
    <subType code="sub-type-43" displayName="Application Withdrawal" content=""/>
    <subType code="sub-type-44" displayName="Pharmacovigilance" content=""/>
    <subType code="sub-type-45" displayName="Undefined Regulatory Activity" content=""/>
    <subType code="sub-type-46" displayName="Appeal" content=""/>
  </section>
</sub_type_vs_toc>